Friulchem Logo

Friulchem

CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.

FCM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005378457 (+1 more)
LEI:
8156003DC8C04217A094
Country:
Italy
Address:
VIA SAN MARCO, 23, 33099 VIVARO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Friulchem is a Contract Development and Manufacturing Organization (CDMO) exclusively dedicated to the animal health sector. The company researches, develops, and manufactures veterinary pharmaceuticals, food supplements, complementary feeds, and premixes for both livestock and pets. Its GMP-authorized services include micronization, granulation, mixing, and spray drying, supported by proprietary drug delivery technologies. Friulchem offers customized formulations and has developed innovative products such as Fc-Cubes®, a highly palatable chewable tablet for pets. Operating on a B2B model, the company provides integrated solutions from development to full-scale manufacturing and packaging at its facilities in Italy and France.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-13 18:49
Delisting Announcement
Modulo Dich. Recesso Friulchem SpA
Italian 610.4 KB
2024-12-23 12:22
Delisting Announcement
REVOCA DELL'AMMISSIONE ALLA NEGOZIAZIONE SU EGM DELLE AZIONI EMESSE DALLA SOCIE…
Italian 205.2 KB
2024-12-07 09:58
Pre-Annual General Meeting Information
Friulchem - Avviso Convocazione - v. 08 - DWF - 2024.12.06 - Final
Italian 335.9 KB
2024-12-07 09:57
Delisting Announcement
CS _Convocazione assemblea Revoca_v. 10 - DWF - 2024.12.06 - Final
Italian 185.5 KB
2024-09-29 16:58
Earnings Release
CS APPROVAZIONE RELAZIONE SEMESTRALE CONSOLIDATA FRIULCHEM SPA
Italian 680.5 KB
2024-04-22 17:44
AGM Information
Approvazione assemblea Friulchem - Convocazione assemblea 8 maggio
Italian 283.4 KB
2024-04-05 11:31
Pre-Annual General Meeting Information
AVVISO DI MESSA A DISPOSIZIONE DOCUMENTAZIONE RELATIVA ALL’ASSEMBLEA DEGLI AZIO…
Italian 211.1 KB
2024-04-05 11:30
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE ASSEMBLEA ORDINARIA E STRAORDINARIA 2023
Italian 349.9 KB
2024-04-04 15:02
Pre-Annual General Meeting Information
verifica dei requisiti di indipendenza e convocazione assemblea straordinaria
Italian 113.0 KB
2024-03-22 18:03
Earnings Release
CdA di Friulchem approva il bilancio consolidato e il progetto di bilancio al 3…
Italian 358.5 KB
2024-01-15 15:00
Report Publication Announcement
CALENDARIO EVENTI SOCIETARI 2024
Italian 138.6 KB
2023-09-22 17:36
Earnings Release
IL CONSIGLIO DI AMMINISTRAZIONE DI FRIULCHEM HA APPROVATO LA RELAZIONE CONSOLI…
Italian 965.1 KB
2023-06-08 10:10
Related Party Transaction
FRIULCHEM APPROVA LA DELIBERA QUADRO INERENTE AL CONTRATTO DI FORNITURA DI MATE…
Italian 149.2 KB
2023-04-21 17:16
AGM Information
L’ASSEMBLEA ORDINARIA DEGLI AZIONISTI DI FRIULCHEM
Italian 440.8 KB
2023-04-06 08:28
Pre-Annual General Meeting Information
AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA DEGLI AZIONISTI FRIULCHEM S.P.A.
Italian 215.5 KB

Automate Your Workflow. Get a real-time feed of all Friulchem filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Friulchem

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Friulchem via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America
CRNX
Develops implantable tech for localized chemotherapy delivery directly into solid tumors.
Virgin Islands (British)
CRTX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America
CRSP
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France
ALCJ
CSL Ltd. Logo
Australia
CSL
CS Medica A/S Logo
Develops patented, CBD-infused medical devices for pain, autoimmune, and stress relief.
Denmark
CSMED
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea
060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America
CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America
CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America
CPIX

Talk to a Data Expert

Have a question? We'll get back to you promptly.